Protalix Biotherapeutics Inc PLX:NYSE American

RT Quote | Last NYSE, VOL From CTA | USD
Last | 1:23 PM EDT
1.13UNCH (UNCH)
Volume
340,585
52 week range
1.09 - 3.55
Loading...
  • Open1.12
  • Day High1.17
  • Day Low1.10
  • Prev Close1.13
  • 52 Week High3.55
  • 52 Week High Date05/05/23
  • 52 Week Low1.09
  • 52 Week Low Date04/18/24

Key Stats

  • Market Cap82.549M
  • Shares Out73.05M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-35.96

KEY STATS

  • Open1.12
  • Day High1.17
  • Day Low1.10
  • Prev Close1.13
  • 52 Week High3.55
  • 52 Week High Date05/05/23
  • 52 Week Low1.09
  • 52 Week Low Date04/18/24
  • Market Cap82.549M
  • Shares Out73.05M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-35.96

RATIOS/PROFITABILITY

  • EPS (TTM)0.07
  • P/E (TTM)16.35
  • Fwd P/E (NTM)12.56
  • EBITDA (TTM)11.651M
  • ROE (TTM)72.50%
  • Revenue (TTM)65.494M
  • Gross Margin (TTM)64.91%
  • Net Margin (TTM)12.69%
  • Debt To Equity (MRQ)60.33%

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Protalix Biotherapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its...
Eliot Forster Ph.D.
Independent Chairman of the Board
Dror Bashan
President, Chief Executive Officer, Director
Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Address
2 University Plaza, Suite 100
Hackensack, NJ
07601
United States

Top Peers

SYMBOLLASTCHG%CHG
DTIL
Precision BioSciences Inc
10.22-0.50-4.66%
CDTX
Cidara Therapeutics Inc
0.715-0.007-0.9695%
TKNO
Alpha Teknova Inc
2.09+0.08+3.98%
EQ
Equillium Inc
1.67-0.06-3.47%
ACRS
Aclaris Therapeutics Inc
1.24+0.01+0.81%